title: Arg462Gln and Asp541Glu polymorphisms in ribonuclease L and prostate cancer risk: a meta-analysis.
abstract: OBJECTIVE
  The association between ribonuclease L (RNASEL) gene polymorphisms and prostate cancer risk has been widely reported, but the results of these studies remained controversial and underpowered. We performed a meta-analysis of 28 studies to evaluate the association between Arg462Gln and Asp541Glu polymorphisms in the RNASEL gene and prostate cancer risk.
  
  
  METHODS
  Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association between RNASEL polymorphisms and prostate cancer risk.
  
  
  RESULTS
  A significantly increased prostate cancer risk was found for the Arg462Gln polymorphism in Africans (Gln/Gln vs Arg/Arg: OR = 2.50, 95%CI = 1.28-4.87; Gln/Gln vs Gln/Arg + Arg/Arg: OR = 2.54, 95%CI = 1.30-4.95), but not in Europeans and Asians. Additionally, the Asp541Glu polymorphism was associated with increased total prostate cancer risk (Glu-allele vs Asp-allele: OR = 1.04, 95%CI = 1.01-1.07; Glu/Glu vs Asp/Asp: OR = 1.22, 95%CI = 1.03-1.46; Glu/Glu vs Glu/Asp + Asp/Asp: OR = 1.09, 95%CI = 1.02-1.16). In the stratified analysis for the Asp541Glu polymorphism, there was a significantly increased prostate cancer risk in Africans and Europeans, and in hospital-based prostate cancer cases.
  
  
  CONCLUSIONS
  The meta-analysis results showed evidence that RNASEL Arg462Gln and Asp541Glu polymorphisms are associated with prostate cancer risk and could be low-penetrance prostate cancer susceptibility biomarkers.
authors.affiliation: Department of Urology, the First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
authors.forename: Yuanyuan
authors.initials: Y
authors.lastname: Mi
authors.forename: Qianqian
authors.initials: Q
authors.lastname: Yu
authors.forename: Zhichao
authors.initials: Z
authors.lastname: Min
authors.forename: Bin
authors.initials: B
authors.lastname: Xu
authors.forename: Lifeng
authors.initials: L
authors.lastname: Zhang
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Ninghan
authors.initials: N
authors.lastname: Feng
authors.forename: Lixin
authors.initials: L
authors.lastname: Hua
keywords: meta-analysis; polymorphism; prostate cancer; ribonuclease L; risk
references.citation: JAMA. 1992 Jan 15;267(3):374-8
references.pmid: 1727960
references.citation: Urol Int. 2007;79(1):44-9
references.pmid: 17627168
references.citation: Cancer Res. 1997 Nov 1;57(21):4707-9
references.pmid: 9354426
references.citation: Prostate. 2007 Jun 1;67(8):849-54
references.pmid: 17407163
references.citation: Br J Cancer. 2005 Mar 28;92(6):1159-64
references.pmid: 15714208
references.citation: Lancet. 1991 Apr 13;337(8746):867-72
references.pmid: 1672966
references.citation: J Interferon Cytokine Res. 2000 Dec;20(12):1091-100
references.pmid: 11152576
references.citation: Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2137-44
references.pmid: 19567509
references.citation: Cell. 1993 Mar 12;72(5):753-65
references.pmid: 7680958
references.citation: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references.pmid: 13655060
references.citation: Control Clin Trials. 1986 Sep;7(3):177-88
references.pmid: 3802833
references.citation: Hum Genet. 2001 Apr;108(4):335-45
references.pmid: 11379880
references.citation: Prostate. 2008 Mar 1;68(4):354-9
references.pmid: 18189233
references.citation: Clin Cancer Res. 2005 Dec 1;11(23):8391-7
references.pmid: 16322300
references.citation: Br J Cancer. 2003 Aug 18;89(4):691-6
references.pmid: 12915880
references.citation: Prostate. 2006 Jan 1;66(1):49-56
references.pmid: 16114055
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: Clin Cancer Res. 2004 Nov 1;10(21):7150-6
references.pmid: 15534086
references.citation: J Clin Oncol. 2008 Apr 1;26(10):1705-9
references.pmid: 18375899
references.citation: Cancer Res. 2003 Oct 15;63(20):6795-801
references.pmid: 14583476
references.citation: Clin Cancer Res. 2006 Oct 1;12(19):5713-9
references.pmid: 17020975
references.citation: BMJ. 1997 Sep 13;315(7109):629-34
references.pmid: 9310563
references.citation: Am J Hum Genet. 2002 May;70(5):1299-304
references.pmid: 11941539
references.citation: Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):588-99
references.pmid: 20086112
references.citation: Am J Hum Genet. 2000 Dec;67(6):1367-75
references.pmid: 11067781
references.citation: Am J Hum Genet. 1974 Jul;26(4):421-43
references.pmid: 4841634
references.citation: JAMA. 1998 Jan 28;279(4):281-6
references.pmid: 9450711
references.citation: Prostate. 2008 Dec 1;68(16):1790-7
references.pmid: 18767027
references.citation: Nat Struct Mol Biol. 2005 Jun;12(6):505-12
references.pmid: 15908960
references.citation: Am J Hum Genet. 2002 Jul;71(1):116-23
references.pmid: 12022038
references.citation: EMBO J. 1993 Aug;12(8):3297-304
references.pmid: 7688298
references.citation: Biomed Pharmacother. 1998;52(9):386-90
references.pmid: 9856285
references.citation: Clin Cancer Res. 2007 Oct 1;13(19):5959-64
references.pmid: 17908993
references.citation: Nucleic Acids Res. 1998 Mar 15;26(6):1522-7
references.pmid: 9490801
references.citation: Science. 1996 Nov 22;274(5291):1371-4
references.pmid: 8910276
references.citation: Nat Genet. 2002 Dec;32(4):581-3
references.pmid: 12415269